Genetic Abnormalities in Non-Hodgkins Lymphoma as Revealed by Conventional and Molecular Cytogenetics Methods of Analyses

Malignant non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of tumors, the histological classification of which based on morphologic evaluation alone is not always possible. Various technological advances in cytogenetics combined with molecular approaches have greatly enhanced our ability to identify genetic abnormalities in any given tumor type. The genetic abnormalities identified with the combination of these methods of analysis have resulted in various histological subtypes of NHL being linked with specific genetic abnormalities. Such a classification based on specific abnormalities has lead to the realization that the same abnormalities associated with initiation, transformation, and progression of the disease have also served as markers of diagnosis, prognosis, and predisposition to a given tumor type, and some abnormalities also served as markers for therapeutic targets. Results of such studies in NHL have not only identified the subsets of various histological types based on specific abnormalities, but, as is evident from recent literature, also set the stage for further evaluation using high-resolution array comparative genomic hybridization (CGH) and expression profiling.